Navigation Links
Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
Date:8/25/2008

COMPANY PRESENTS AT THOMAS WEISEL WEDNESDAY, SEPTEMBER 3RD AND NEWSMAKERS

IN THE BIOTECH INDUSTRY CONFERENCE THURSDAY, SEPTEMBER 4TH

SAN DIEGO, Aug. 25 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer will be presenting at both the Thomas Weisel Healthcare Conference in Boston and the NewsMakers in the Biotech Industry Conference in New York.

The presentation at the Thomas Weisel Conference in Boston at the Four Seasons takes place Wednesday, September 3, 2008 at 2:05 p.m. Eastern Time (ET) / 11:05 a.m. Pacific Time (PT). The live presentation will be simultaneously webcast and may be accessed on the Company's website at http://www.neurocrine.com.

The presentation at the NewsMakers in the Biotech Industry Conference in New York at the Millennium Broadway will take place Thursday, September 4, 2008 at 10:00 a.m. Eastern Time (ET) / 7:00 a.m. Pacific Time (PT). The live presentation will be simultaneously webcast and may be accessed on the Company's website at http://www.neurocrine.com.

If you are unable to attend these webcasts and would like further information on this announcement please contact the Investor Relations Department at Neurocrine Biosciences at (858) 617-7600. Viewers are encouraged to visit the website approximately 5 minutes prior to the presentations to download or install any necessary software. A replay of both presentations will be available approximately one hour after the conclusion of the live event and will be archived on the Company's website for two weeks.

About Neurocrine

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, irritable bowel syndrome (IBS), anxiety, depression, pain, diabetes, benign prostatic hyperplasia (BPH) and other neurological and endocrine related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Neurocrine Biosciences Reports Second Quarter 2008 Results
2. Neurocrine Biosciences Announces Conference Call and Webcast To Present Second Quarter 2008 Financial Results
3. Neurocrine Biosciences to Present at the 2008 Citi Investment Research Global Health Care Conference
4. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2008 Financial Results
5. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2007 Financial Results
6. Neurocrine Announces Appointment of Kevin Gorman, Ph.D., as President and Chief Executive Officer
7. Neurocrine Announces Work Force Restructuring
8. Neurocrine Receives Approvable Letter for Indiplon Capsules with Additional Safety and Efficacy Data Required by FDA
9. Neurocrine Biosciences Announces Conference Call and Webcast to Provide Indiplon Update
10. Neurocrine Biosciences and Dainippon Sumitomo Pharma (DSP) Announce Agreement to Develop and Commercialize Indiplon in Japan
11. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ROTTERDAM, the Netherlands and LAGUNA HILLS, ... that The Institute of Cancer Research, London ... will use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify ... high-risk trial known as MUK nine . The University ... this trial, which is partly funded by Myeloma UK, and ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that ... Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los ...
(Date:10/10/2017)... ... October 10, 2017 , ... USDM ... firm for the life sciences and healthcare industries, announces a presentation by Subbu ... , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present a ...
(Date:10/9/2017)... ... 2017 , ... The Giving Tree Wellness Center announces the ... of consumers who are incorporating medical marijuana into their wellness and health regimens. ... operators of two successful Valley dispensaries, The Giving Tree’s two founders, Lilach Mazor ...
Breaking Biology Technology:
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... Annual Report on Form 10-K on Thursday April 13, 2017 with ... ... Relations section of the Company,s website at http://www.nxt-id.com  under "SEC ... . 2016 Year Highlights: Acquisition ...
(Date:4/11/2017)... 11, 2017 Crossmatch®, a globally-recognized leader ... today announced that it has been awarded a ... Activity (IARPA) to develop next-generation Presentation Attack Detection ... "Innovation has been a driving force within Crossmatch ... allow us to innovate and develop new technologies ...
(Date:4/11/2017)... April 11, 2017 NXT-ID, Inc. (NASDAQ: ... company, announces the appointment of independent Directors Mr. Robin ... its Board of Directors, furthering the company,s corporate governance and ... Gino Pereira ... look forward to their guidance and benefiting from their considerable ...
Breaking Biology News(10 mins):